Tissue Plasminogen Activator
Sponsors
University of Washington, National Heart, Lung, and Blood Institute (NHLBI), University of California, San Diego, University Health Network, Toronto, University of Calgary
Conditions
AbscessAcute Respiratory Distress SyndromeAll Patients With Ischemic Cerebrovascular Stroke Aged ≥18 Years of Both SexAll fibrinolytic agents either non-Aneurysmal Subarachnoid HemorrhageAngina PectorisCardiovascular DiseasesCentral Retinal Vein Occlusion
Phase 1
Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke
CompletedNCT00283088
Start: 2003-10-31End: 2009-05-31Target: 130Updated: 2011-01-12
Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion
CompletedNCT01581411
Start: 2012-01-31End: 2015-11-30Updated: 2018-08-06
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
WithdrawnNCT01878136
Start: 2015-03-31End: 2016-09-30Updated: 2015-11-11
Phase 2
Safety and Effectiveness of tPA in Intra-abdominal Abscesses
TerminatedNCT00417768
Start: 2005-07-31End: 2013-11-30Updated: 2014-01-14
Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
NCT01098890
Start: 2009-10-31End: 2012-04-30Target: 12Updated: 2010-11-11
Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke
CompletedNCT02388061
Start: 2015-03-23End: 2018-02-28Updated: 2018-03-30
Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)
RecruitingNCT05766124
Start: 2024-11-01End: 2028-06-30Target: 30Updated: 2026-01-05
Phase 3
Myocardial Infarction Triage and Intervention Project (MITI)
CompletedNCT00000468
Start: 1988-04-30End: 1992-03-31Updated: 2016-02-09
Thrombolysis in Myocardial Ischemia Trial (TIMI III)
CompletedNCT00000472
Start: 1989-04-30End: 1995-06-30Updated: 2016-03-16
Thrombolysis in Myocardial Infarction (TIMI)
CompletedNCT00000505
Start: 1983-04-30End: 1990-12-31Updated: 2016-03-16
Adjunctive, Low-dose tPA in Primary PCI for STEMI
CompletedNCT03335839
Start: 2018-04-01End: 2025-02-12Updated: 2025-09-26
Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)
WithdrawnNCT04453371
Start: 2020-10-15End: 2021-02-15Updated: 2021-03-12
Phase 4
Unknown Phase
Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis
CompletedNCT01451320
Start: 1993-01-31End: 2009-12-31Updated: 2011-10-13
Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis
CompletedNCT01451320
Start: 1993-01-31End: 2009-12-31Updated: 2011-10-13
Thrombolytic Care During Inter-hospital Transfer
CompletedNCT02752256
Start: 2015-10-31End: 2017-10-31Updated: 2019-07-05
Regisry of the Stroke Patients in Assiut University Hospital
NCT03392792
Start: 2018-12-30End: 2018-12-30Target: 1Updated: 2018-01-08
Fibrinolytic-Associated Urticaria, Angioedema, and Type I Hypersensitivity Reactions from Various Indications
Active, not recruitingTCTR20190607003
Start: 2019-01-21Updated: 2026-03-30
Application of tPA in Suprachoroidal and Subretinal Hemorrhage
RecruitingNCT05736757
Start: 2022-12-01End: 2026-07-31Target: 20Updated: 2023-02-21
Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE
SuspendedNCT06310018
Start: 2027-01-01End: 2028-12-31Target: 60Updated: 2026-01-21